Cardinal Health warned Thursday that if President Donald Trump follows through with threatened tariffs next month, higher ...

Cardinal Health's pharmaceutical and specialty solutions segment profit increased 7% to $531 million in the second quarter.

Citi analyst Daniel Grosslight increased the price target for Cardinal Health (NYSE:CAH) shares to $130 from the previous $129, while keeping a Neutral rating on the stock. The adjustment follows ...

Cardinal Health (CAH) came out with quarterly earnings of $1.93 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.82 per share a year ago. These ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Cardinal Health reported an increase in revenue for two of its segments, while the departure of Optimum impacted its Pharmaceuticals segment.

Cardinal Health has reported second quarter revenue for its “other” businesses, which includes at-Home Solutions, increased 13% to $1.3 billion.

Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.

Management raised fiscal 2025 EPS guidance to $7.85-$8, a $0.10 increase at the midpoint, reflecting strong Pharma performance and contributions from recent acquisitions. The company expects Q3 to be ...

Leerink raised the firm’s price target on Cardinal Health (CAH) to $156 from $138 and keeps an Outperform rating on the shares. Q2 results ...

Cardinal Health Inc (CAH) revealed a profit for its second quarter that increased from last year and beat the Street estimates. The ...

Hello, and welcome to the Second Quarter Fiscal Year 2025 Cardinal Health Inc. Earnings Conference Call. My name is George, and I'll be coordinator for today's event. Please note, this conference is ...